ENTRY       D00592                      Drug
NAME        Dapsone (USP);
            Diaphenylsulfone (JAN);
            Aczone (TN)
PRODUCT     ACZONE (ALMIRALL)
            ACZONE (Allergan)
            ACZONE (Allergan)
            ACZONE (Almirall)
  GENERIC   DAPSONE (ANI Pharmaceuticals)
            DAPSONE (Amneal Pharmaceuticals NY LLC)
            DAPSONE (Aphena Pharma Solutions - Tennessee)
            DAPSONE (Cosette Pharmaceuticals)
            DAPSONE (Encube Ethicals Private Limited)
            DAPSONE (Golden State Medical Supply)
            DAPSONE (Jacobus Pharmaceutical Company)
            DAPSONE (Jacobus Pharmaceutical Company)
            DAPSONE (Mayne Pharma Commercial LLC)
            DAPSONE (Mylan Pharmaceuticals)
            DAPSONE (NORTHSTAR RX LLC)
            DAPSONE (Nostrum Laboratories)
            DAPSONE (Pacific Pharma)
            DAPSONE (Rising Pharma Holdings)
            DAPSONE (Taro Pharmaceuticals U.S.A.)
            DAPSONE (Taro Pharmaceuticals U.S.A.)
            DAPSONE (Taro Pharmaceuticals U.S.A.)
            DAPSONE (Torrent Pharmaceuticals Limited)
FORMULA     C12H12N2O2S
EXACT_MASS  248.0619
MOL_WEIGHT  248.3009
CLASS       Metabolizing enzyme substrate
             DG02855  CYP2E1 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Same as: C07666
            Therapeutic category: 2699 6231
            ATC code: D10AX05 J04BA02
            Product: D00592<JP/US>
EFFICACY    Antibacterial (leprostatic)
  DISEASE   Acne vulgaris [DS:H01445]
            Dermatitis herpetiformis [DS:H01362]
            Leprosy [DS:H00344]
COMMENT     Diaminodiphenylsulfone derivative
            Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency [DS:H00668] are more prone to hemolysis with the use of Dapsone.
            Suppression of dermatitis herpetiformis
TARGET      dihydropteroate synthase [KO:K00796]
  PATHWAY   ko00790(K00796)  Folate biosynthesis
METABOLISM  Enzyme: CYP2E1 [HSA:1571], CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D10 ANTI-ACNE PREPARATIONS
               D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE
                D10AX Other anti-acne preparations for topical use
                 D10AX05 Dapsone
                  D00592  Dapsone (USP) &lt;JP/US&gt;
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J04 ANTIMYCOBACTERIALS
               J04B DRUGS FOR TREATMENT OF LEPRA
                J04BA Drugs for treatment of lepra
                 J04BA02 Dapsone
                  D00592  Dapsone (USP) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antimycobacterials
              Antimycobacterials, Other
               Dapsone
                D00592  Dapsone (USP)
             Dermatological Agents
              Topical Anti-infectives
               Antibacterials, dermatological
                Dapsone
                 D00592  Dapsone (USP)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              26  Epidermides
               269  Miscellaneous
                2699  Others
                 D00592  Dapsone (USP); Diaphenylsulfone (JAN)
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               623  Leprostatics
                6231  Sulfones
                 D00592  Dapsone (USP); Diaphenylsulfone (JAN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG02855  CYP2E1 substrate
               D00592  Dapsone
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D00592  Dapsone
            Antimicrobials [BR:br08307]
             Antibacterials
              Folic acid biosynthesis inhibitor
               Diaminodiphenyl sulfone
                D00592  Dapsone (USP) &lt;JP/US&gt;
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00592
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D00592
            Prodrugs [br08324.html]
             D00592
DBLINKS     CAS: 80-08-0
            PubChem: 7847658
            ChEBI: 4325
            LigandBox: D00592
            NIKKAJI: J4.247A
ATOM        17
            1   S4a S    21.9800  -14.6136
            2   C8y C    23.1922  -15.3246
            3   C8y C    20.7736  -15.3187
            4   O3c O    20.9776  -13.6228
            5   O3c O    22.9708  -13.6228
            6   C8x C    24.4045  -14.6195
            7   C8x C    23.1922  -16.7234
            8   C8x C    19.5614  -14.6136
            9   C8x C    20.7736  -16.7175
            10  C8x C    25.6050  -15.3187
            11  C8x C    24.4045  -17.4168
            12  C8x C    18.3433  -15.3187
            13  C8x C    19.5614  -17.4168
            14  C8y C    25.6167  -16.7234
            15  C8y C    18.3433  -16.7175
            16  N1a N    26.8174  -17.4285
            17  N1a N    17.1369  -17.4168
BOND        18
            1     1   2 1
            2     1   3 1
            3     1   4 2
            4     1   5 2
            5     2   6 2
            6     2   7 1
            7     3   8 2
            8     3   9 1
            9     6  10 1
            10    7  11 2
            11    8  12 1
            12    9  13 2
            13   10  14 2
            14   12  15 2
            15   14  16 1
            16   15  17 1
            17   11  14 1
            18   13  15 1
///
